• Regimens, Medicines, and Physiotherapy

  Orkambi Approved in Europe for Young Children with Cystic Fibrosis

  Posted by Cystic Fibrosis News Moderator on January 30, 2019 at 6:56 pm

  The European Commission has approved Orkambi’s label extension to include cystic fibrosis patients ages 2-5 with two copies of the 508del mutation. Click here to learn more.

  Do you agree with this decision? Will it impact you or anyone you know?

  Cystic Fibrosis News Moderator replied 5 years, 10 months ago 1 Member · 0 Replies
• 0 Replies

Log In to Reply